CN107714732A - A kind of medicine containing American cockroach and capecitabine and its application - Google Patents
A kind of medicine containing American cockroach and capecitabine and its application Download PDFInfo
- Publication number
- CN107714732A CN107714732A CN201611174010.2A CN201611174010A CN107714732A CN 107714732 A CN107714732 A CN 107714732A CN 201611174010 A CN201611174010 A CN 201611174010A CN 107714732 A CN107714732 A CN 107714732A
- Authority
- CN
- China
- Prior art keywords
- american
- cockroach
- capecitabine
- extract
- medicinal powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title claims abstract description 90
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 229960004117 capecitabine Drugs 0.000 title claims abstract description 89
- 241000238675 Periplaneta americana Species 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 230000006907 apoptotic process Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 241000287219 Serinus canaria Species 0.000 claims description 9
- 240000000233 Melia azedarach Species 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 229940079593 drug Drugs 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000011580 nude mouse model Methods 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 201000004101 esophageal cancer Diseases 0.000 description 8
- 239000000890 drug combination Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000637 radiosensitizating effect Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000035519 G0 Phase Effects 0.000 description 4
- 230000010190 G1 phase Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- -1 sorbierite Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000238660 Blattidae Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000500891 Insecta Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of medicine containing American cockroach and capecitabine and its application, the active component of described medicine includes American cockroach and capecitabine.Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder.Described medicine constituent can be 1000~2500 parts of American-cockroach-extract by weight, 200~300 parts of capecitabine；It can also be 500~800 parts of American cockroach medicinal powder, 200~300 parts of capecitabine.The pharmaceutical composition of the present invention has very strong Apoptosis to tumour, tumour can effectively be treated, positive effect is used alone better than American cockroach and capecitabine, illustrate that the two has a synergistic function after being used cooperatively under present invention proportioning, potential applicability in clinical practice is good.
Description
Technical field
The invention belongs to pharmaceutical formulation field, it is especially useful in a kind of medicine containing American cockroach and capecitabine and its should
With.
Background technology
Capecitabine is a kind of new xeloda, can be sticked after oral in the form of prototype through stomach and intestine rapidly
Film absorbs, and after liver metabolism, the selective tumour cell for acting on high expression thymidine phosphorylase (TP), plays anti-
Tumor promotion, the characteristic of capecitabine three steps activation in vivo make the medicine with targeting, and radiotherapy can be with
Increase the expression of class TNF A, so as to increase TP activity, normal tissue joins without influence, therefore with radiotherapy
Its targeting can be strengthened by closing application.External clinical research shows that capecitabine is to the tumor in upper digestive tract such as cancer of the esophagus, nasopharynx
Cancer, stomach cancer and cancer of pancreas etc. have sensitization.
American cockroach (Periplaneta american) belongs to Insecta, Blattidae, is commonly called as cockroach.American cockroach is as medicine
With initially seeing《Sheng Nong's herbal classic》, for controlling bloody sputum disease, fever and chills, broken accumulation, laryngopharynx numbness, interior cold s.m.p.Sent out at present in research
Existing American cockroach ethanol extract is white to chronic marrow-derived leukocythemia (K562), promyelocytic leukemia (HL60), mouse in vitro
Blood disease (P388D1) cell line, nasopharyngeal carcinoma (CNE), lung cancer (A549), oral epithelium cancer (KB) cell line, oophoroma
(HO8910), cervical carcinoma (Hela) and prostate cancer (PC3) cell line, the cancer of the esophagus (Ecal09), sdenocarcinoma of stomach (BGC823), colon
Cancer (LS174T) cell line has growth inhibition effect.
Have not yet to see the report of American cockroach and its extract joint capecitabine in the radiosensitivity for improving tumour
Road.
The content of the invention
The invention provides a kind of medicine containing American cockroach and capecitabine, described medicine is improving putting for tumour
Significant effect in sensitiveness is penetrated, its action effect is substantially better than American cockroach and capecitabine independent medication effect.
The active component of medicine of the present invention includes American cockroach and capecitabine.
Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder.
Further, the active component of described medicine by weight, including：American-cockroach-extract 1000~2500
Part, 200~300 parts of capecitabine；Preferably, 2500 parts of American-cockroach-extract, 300 parts of capecitabine.
American-cockroach-extract preparation method is as follows：
American cockroach, which crushes to be placed in ethanol, to be soaked, and refluxing extraction 2~3 times, is concentrated into no alcohol taste, obtains extract solution, past
Water is added in extract solution, after being well mixed, stands, cools down, filtering, be concentrated under reduced pressure, be drying to obtain；
Further, American-cockroach-extract of the present invention can be Kangfuxin Liquid, meet WS3-B-3674-2000
(Z) to the limit standard of " Kangfuxin Liquid " in, 0.72mg must not be less than containing total amino acid per 1ml, such as commercially available Kangfuxin Liquid.
It is also possible that the active component of described medicine is by weight, including：500~800 parts of American cockroach medicinal powder,
200~300 parts of capecitabine；Preferably, 800 parts of American cockroach medicinal powder, 300 parts of capecitabine.
American cockroach medicinal powder preparation method is：
A. adult bombay canary is placed in vacuum desiccator, it is 2~5% to be dried at 20~55 DEG C to water content, is obtained
Dry adult bombay canary；
B. it is -200 DEG C~-50 DEG C ultralow the adult bombay canary of the drying obtained in step a to be placed in into temperature setting
60~300 mesh are crushed in warm pulverizer, produce American cockroach medicinal powder.
Although selected in the specific embodiment of the invention through intestines and stomach absorbable preparation to embody the treatment of pharmaceutical composition effect
Fruit, however, this form of medication that can not be used to limit pharmaceutical composition of the present invention.With reference to modern separating and purifying technology or/and
Preparation means, those skilled in the art can also be prepared into transdermal absorption formulation, outer by American cockroach or its extract after purification
With other form of medication such as lotion, et al. Ke preparation, injections, so as to strengthen target-oriented drug, improve drug effect or avoid not
Necessary toxicity.
Present invention also offers a kind of compound formulation to cancer with Apoptosis, and it is extracted by American cockroach
Thing or American cockroach medicinal powder and capecitabine are as active component, plus pharmaceutically acceptable auxiliary material or auxiliary element preparation
Into preparation.
Described cancer includes：The cancer of the esophagus, nasopharyngeal carcinoma, breast cancer, oophoroma, stomach cancer, colorectal cancer.
Pharmaceutically acceptable auxiliary material of the present invention, refer to the material being included in addition to the active ingredient (s in formulation, bag
Include but be not limited only to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, regulation
Agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc..Adhesive include syrup, Arabic gum, gelatin, sorbierite,
Tragacanth, cellulose and its derivates (such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or hydroxypropyl methylcellulose
Element etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.；Filler include lactose, Icing Sugar, dextrin, starch and its
Derivative, cellulose and its derivates, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate), sorb
Alcohol or glycine etc.；Lubricant includes superfine silica gel powder, magnesium stearate, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, poly- second
Glycol etc.；Disintegrant includes starch and its derivative (such as sodium carboxymethyl starch, Explotab, pregelatinized starch, improvement shallow lake
Powder, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.；Wetting agent includes dodecyl sulphate
Sodium, water or alcohol etc.；Antioxidant packages are containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.；Bacteriostatic agent includes
0.5% phenol, 0.3% cresols, 0.5% anesin etc.；Conditioning agent includes hydrochloric acid, citric acid, potassium hydroxide (sodium), citron
Sour sodium and buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate) etc.；Emulsifying agent includes Tween-80, aliphatic acid sorb
Smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.；Solubilizer includes Tween-80, bile, glycerine etc..
The pharmaceutically acceptable complementary composition, it has certain physiologically active, but the addition of the composition will not change
Become the leading position of above-mentioned health products or pharmaceutical composition in treatment of diseases, and only play auxiliary effect, these are auxiliary
Assist effect is only the utilization to the composition known activity, is the usual adjuvant treatment modality of field of medicaments.
In above-mentioned compound formulation, the weight proportion of American-cockroach-extract and capecitabine is (1000~2500)：(200
~300)；Preferably, the weight proportion of American-cockroach-extract and capecitabine is 2500：300.
Above-mentioned preparation can also be that the weight proportion of American cockroach medicinal powder and capecitabine is (500~800)：(200~
300)；Preferably, the weight proportion of American cockroach medicinal powder and capecitabine is 800：300.
Further, in the preparation, the content of the every big Lian extracts in daily unit formulation Central America and capecitabine is total
Count 18.7g；The content of the every big Lian medicinal powder in daily unit formulation Central America and capecitabine amounts to 7.3g." every daily unit
Dosage " refers to the preparation total amount taken daily.
Embodiment
The preparation of the American-cockroach-extract of embodiment 1
American-cockroach-extract：500g American cockroaches, which crush to be placed in 90% ethanol, soaks 12h, refluxing extraction 2 at 85 DEG C
~3 times, no alcohol taste is concentrated into, obtains extract solution, 1500g water is added into extract solution, after being well mixed, is stood, cooling, mistake
Filter, it is concentrated under reduced pressure, dries, crushing and produce.
The preparation of the American cockroach medicinal powder of embodiment 2
American cockroach medicinal powder：Adult bombay canary is placed in vacuum desiccator, dried at 20~55 DEG C to water content
For 2%, dry adult bombay canary is obtained, it is -100 DEG C super that the adult bombay canary of obtained drying is placed in into temperature setting
60~300 mesh are crushed in Lowtemperaturepulverizer, produce American cockroach medicinal powder.
Embodiment 3
The medicine is American-cockroach-extract 2500mg and capecitabine 300mg combination medicines in embodiment 1.
Embodiment 4
The medicine is American-cockroach-extract 1000mg and capecitabine 200mg combination medicines in embodiment 1.
Embodiment 5
The medicine is American-cockroach-extract 2500mg and capecitabine 200mg combination medicines in embodiment 1.
Embodiment 6
The medicine is American-cockroach-extract 1000mg and capecitabine 300mg combination medicines in embodiment 1.
Embodiment 7
The medicine is American cockroach medicinal powder 800mg and capecitabine 300mg combination medicines in embodiment 2.
Embodiment 8
The medicine is American cockroach medicinal powder 500mg and capecitabine 200mg combination medicines in embodiment 2.
Embodiment 9
The medicine is American cockroach medicinal powder 800mg and capecitabine 200mg combination medicines in embodiment 2.
Embodiment 10
The medicine is American cockroach medicinal powder 500mg and capecitabine 300mg combination medicines in embodiment 2.
The combination medicine of American cockroach and capecitabine described in any one of 3~embodiment of above example 10 can be with
Plus pharmaceutically conventional auxiliary material or complementary composition, capsule, tablet, sustained release is made according to technological means commonly used in the art
The oral formulations such as preparation, liquid preparation.
Beneficial effects of the present invention are proved below by way of specific pharmacodynamic experiment.Wherein, used in test example 1 and test example 2
American-cockroach-extract+capecitabine composition be the medicine described in embodiment 3；U.S. used in test example 1 and test example 2
The big Lian medicinal powder+capecitabine composition in continent is the medicine described in embodiment 7.
Test example 1
First, research of the medicine of the present invention to esophageal carcinoma cell line EC9706 radiosensitizing effects
1. experiment material
1.1 experimental cell
Human esophagus cancer cell strain EC9706 (is provided) by Chengdu University of Traditional Chinese Medicine's Basic Experimental Teaching Center.With containing 10% tire ox blood
Clear RPMI 1640 culture mediums are placed in 37 DEG C, 5%CO2Constant temperature training case in cultivate, with 0.25%EDTA pancreatin had digestive transfer cultures,
Exponential phase of growth cell is taken to be tested.
1.2 experimental drugs and configuration
Capecitabine (Xeloda) (Shanghai Co., Ltd of Roche Group)：Specification：500mg/ pieces.
1.3 experiment packet
It is divided into 6 groups：Control group, American cockroach medicinal powder group, American-cockroach-extract group, capecitabine group, American cockroach
Extract+capecitabine group, American cockroach medicinal powder+capecitabine group.
1.4 radiosensitizations are tested
1.4.1 illuminating method
Irradiated using 6MeV x-rays linear accelerator, irradiation distance 100cm, irradiation field is 10cm × 10cm, at room temperature
Single fraction irradiation.Exposure dose 2Gy, ensure that each group cell is illuminated.
1.4.2 the measure of cell inhibitory rate
Take the logarithm growth period EC9706 cell, by 1 × 104/ ml, 100 μ l/ holes are inoculated with 96 orifice plates, are divided into 6 described in 1.3
Individual group, every group sets 6 multiple holes.After cell is completely adherent, each group adds corresponding pastille culture medium, and control group is culture completely
Base, it is placed in 37 DEG C, 5%CO2After incubator is incubated culture 24h, wavelength 450nm optical density is determined on ELIASA using MTS
It is worth (OD values), calculates inhibition rate of tumor cell (%), calculation formula is as follows.
Inhibiting rate (%)=(1- administration groups OD values/control group OD values) × 100%
1.4.3 colony-forming test determines Radiosensitizing
EC9706 after the illuminating method irradiation as described in 1.4.1 is placed into 4h in incubator, obtains sublethal damage
To repair, homogeneous cell suspension then is mixed into through the digestion of 0.25% tryptic digestive juice, 6 orifice plates are inoculated in per hole 2ml
In, ensure per hole cell number to be 1000 or so.It is divided into 6 groups described in 1.3,3 multiple holes of every group of setting, each group adds corresponding
Pastille culture medium, control group are complete medium.Continue to cultivate 14d, daily Microscopic observation, when each thin in constant incubator
When growing up to the colony more than 50 cells around born of the same parents, add methanol and fix, the dyeing of Ji's nurse Sa, count under mirror each Drug level group
Colony number.Colony-forming efficiency represents that cell survival fraction is represented with SF with PE.Model is clicked using more targets of SPSS statistical softwares
Analyzed, draw each group parameter (N, D0、Dq、SF2、SERDq)。
Colony-forming efficiency (PE)=colony number/inoculating cell number × 100%
Cells survival fraction (SF)=each exposure dose PE/ does not irradiate PE × 100%
Enhance-ment ratio (SERDq)=the Dq values irradiated merely/compare the Dq values of dosing
1.4.4 flow cytometry
Take the logarithm growth period EC9706 cell, by 1 × 104/ ml, 100 μ l/ holes are inoculated with 96 orifice plates, are divided into 6 described in 1.3
Individual group, every group sets 6 multiple holes, separately sets one group of blank control as negative control group.Each group adds corresponding pastille culture medium, blank
Group and control group are complete medium, are placed in 37 DEG C, 5%CO2 incubators incubation culture 24h.After abandoning medicine, in addition to blank group, often
Group cell illuminating method as described in 1.4.1 is irradiated, and 24h is then incubated in culture, and then pancreatin digests, 1000r/min centrifugations
5min, supernatant is abandoned, D-hanks is cleaned 2 times, and overnight, centrifugation discards ethanol, and D-hanks is washed 2 times again for 80% 4 DEG C of ethanol fixation, uses
Rnase (whole mass concentration 0.02mg/ml), PI (whole mass concentration is 0.1mg/ml) lucifuge dyeing 30min, flow cytometer point
Analyse cell cycle distribution situation.
1.5 statistical method
Analyzed using SPSS17.0 statistical softwares, data information represents that multigroup is compared from single factor test variance with x ± s
Analyze, compare two-by-two using independent samples t test in group, with P<0.05 is that difference is statistically significant, P<0.01 is that difference has
There is significant statistical significance.
2 results
The measure of 2.1 cell inhibitory rates
The American cockroach medicinal powder of table 1, American-cockroach-extract and the two combine card respectively and accompany his shore to EC9706 Carbazole alkaloids
Rate influence (n=6,)
| Group | Dosage (μ g/ml) | OD values | Inhibiting rate (%) |
| Control group | - | 4.37±0.43△ | - |
| Capecitabine group | 6 | 1.89±0.13* | 56.75 |
| American-cockroach-extract group | 50 | 3.26±0.10*△ | 25.40 |
| American cockroach medicinal powder group | 16 | 2.99±0.09*△ | 31.58 |
| American-cockroach-extract+capecitabine group | 50+6 | 1.46±0.07*△ | 66.59 |
| American cockroach medicinal powder+capecitabine group | 16+6 | 1.31±0.07*△ | 70.02 |
Note：Compared with control group, * P ＜ 0.05；Compared with capecitabine group, △ P ＜ 0.05.
After capecitabine it can be seen from the result of table 1 and American-cockroach-extract drug combination, to human esophagus cancer cell strain
The inhibitory action of EC9706 cell propagation has statistics apparently higher than capecitabine and American-cockroach-extract is used alone
Meaning；Capecitabine and the suppression after American cockroach medicinal powder drug combination, bred to human esophagus cancer cell strain EC9706 cell
Effect has statistical significance apparently higher than capecitabine and American-cockroach-extract is used alone；
2.2 pairs of EC9706 radiotherapy sensitizations
Compared with capecitabine group, American-cockroach-extract+capecitabine group and American cockroach medicinal powder+capecitabine group pair
EC9706 radiotherapy effect of enhanced sensitivity is notable.
The American cockroach medicinal powder of table 2, American-cockroach-extract and the two combine card respectively and accompany his shore to EC9706 radiotherapies
Enhanced sensitivity ratio (SER)
Note：Compared with capecitabine group, △ P ＜ 0.05.
After capecitabine it can be seen from the result of table 2 and American-cockroach-extract drug combination, to human esophagus cancer cell strain
EC9706 radiosensitizing effect has statistical significance apparently higher than capecitabine is used alone；Capecitabine is big with America
After Lian medicinal powder drug combinations, to human esophagus cancer cell strain EC9706 radiosensitizing effect apparently higher than Ka Peita is used alone
Shore, there is statistical significance.
The influence of 2.3 cell cycles
The American cockroach medicinal powder of table 3, American-cockroach-extract and the two combine the influence that card accompanies his shore cell cycle respectively
(n=6,)
Note：Compared with control group, * P ＜ 0.05；Compared with capecitabine group, △ P ＜ 0.05.
As can be seen from Table 3：Capecitabine group G0/G1 phase cell proportions are significantly raised, illustrate that it suppresses tumour cell
The mechanism of action of propagation is probably to block the G0/G1 phases；The S phase ratios of American-cockroach-extract group increase, and illustrate that it suppresses tumour
The mechanism of action of propagation is probably to block the S phases.And capecitabine and American-cockroach-extract drug combination group act on EC9706
After cell line 24h, G0/G1 phase cell quantities increase, and ratio substantially increases, but S phases and G2/M phases ratio decline, and illustrate both connection
Cell cycle has retardation after sharing medicine, make tumour cell it is more rest on the G0/G1 phases, both hinder after being used in combination
The stagnant more alone medicine group of effect is high, generates the effect of Synergistic；Similarly analysis can obtain, and American cockroach medicinal powder joins with capecitabine
With the rear inhibitory action to tumor cell proliferation apparently higher than independent medication group, both have the function that Synergistic at combination.
Test example 2
2nd, research of the medication combined radiotherapy of the present invention to tumor-bearing mice
1. experiment material
1.1 experimental animal
BALB/C-nu/nu nude mices, SPF levels, 4~5 week old, 15~17g of body weight, nude mice are raised under Clean Facility, permanent
Warm (24~26 DEG C), cage tool, bedding and padding, drinking water and feed are sterile-processed, and experimenter strictly carries out sterile working.
1.2 experimental cell
Human esophagus cancer cell strain EC9706 (is provided) by Chengdu University of Traditional Chinese Medicine's Basic Experimental Teaching Center.
1.3 experimental drugs and configuration
Capecitabine (Xeloda) (Shanghai Co., Ltd of Roche Group)：Specification：500mg/ pieces.
Illuminating method：Using Beijing company of Daheng KB1800 type medical computerized linear accelerators, 6MV-X lines are irradiated,
SSD is 100cm, dosage 2Gy/min.
1.4 experimental method
1.4.1 Nude Mouse Model is established
Human esophagus cancer EC9706 cell lines are subjected in vitro culture to exponential phase, with 0.25% trypsase and
0.04%EDTA vitellophags, blow and beat repeatedly to be collected into after single cell suspension in centrifuge tube.1000rpm/min centrifuges 5min,
Abandoning supernatant, PBS are resuspended after washing 2 times with PBS, and light Microscopic observation number of alive cell ＞ after blue dyeing is expected at 0.4%
95%, count, be configured to 1 × 107Concentration, aseptically fix nude mice.After armpit skin routine disinfection on the right side of nude mice
Hold 1ml asepsis injectors forelimb armpit on the right side of nude mice and 0.2ml cell suspensions are subcutaneously injected, form locality tumor model.Note
The local obvious skin mound of appearance is penetrated, occurs the big lesser tubercle of grain grain after 5 days, Transplanted tumor model is established, tumor formation rate 100%.
1.4.2 packet and administration
BALB/C-nu/nu SPF levels nude mice 48 use in experiment, inoculation human esophagus cancer EC9706 cell suspensions, visible after 11d
The subcutaneous tumour for having about 0.5cm × 0.5cm sizes is generated, and 48 nude mices are randomly divided into 6 groups, every group 8：(1) control group is not
Carry out perfusion；(2) capecitabine group, by 300mg/kg gavage capecitabines；(3) American cockroach medicinal powder group, is filled by 800mg/kg
Stomach American cockroach medicinal powder；(4) American-cockroach-extract group, by 2500mg/kg gavage American-cockroach-extracts；(5) American cockroach
Extract+capecitabine group, by 2500mg/kg+300mg/kg gavages American-cockroach-extract and capecitabine；(6) America is big
Lian medicinal powder+capecitabine group, by 800mg/kg+300mg/kg gavage American cockroach medicinal powder and capecitabine.In addition to control group, often
The daily gavage of group mouse 1 time, continuous 28 days, meanwhile, every group of mouse x-ray bombardment tumor by local 4Gy/ times × 4 times, the next day enter
Row 1 time.
After last therapeutic 72h, nude mice tumorous size is measured, nude mice is put to death with spinal cord dislocation method, nude mice dorsal position is fixed,
To right upper extremity skin routine disinfection, knurl body at armpit is peeled off, scales/electronic balance weighing knurl body tumour is used after being blotted with filter paper, is calculated swollen
Knurl tumour inhibiting rate.
Tumour inhibiting rate (%)=(the average knurl weight of the average knurl weight-treatment group of control group) average knurl weight × 100% of/control group
1.5 statistical method
Analyzed using SPSS17.0 statistical softwares, data information represents that multigroup is compared from single factor test variance with x ± s
Analyze, compare two-by-two using independent samples t test in group, with P<0.05 is that difference is statistically significant, P<0.01 is that difference has
There is significant statistical significance.
2. experimental result
As can be seen from Table 4：Compared with control group, each experimental group can reduce tumour inhibiting rate, and tumour inhibiting rate is 37.1%~
72.17%, wherein American-cockroach-extract+capecitabine group and American cockroach medicinal powder+capecitabine group tumor killing effect is notable.Card
The tumour inhibiting rate after his shore and American-cockroach-extract combined radiotherapy is trained apparently higher than American cockroach and capecitabine independent medication simultaneously
Tumour inhibiting rate after combined radiotherapy；Tumour inhibiting rate after capecitabine and American cockroach medicinal powder combined radiotherapy apparently higher than American cockroach and
Tumour inhibiting rate after capecitabine independent medication and combined radiotherapy.By can be seen that capecitabine and the present invention in the data in upper table
Treating cancer is used in combination in described American cockroach, substantially increases the therapeutic action to tumour.
The American cockroach medicinal powder of table 4, American-cockroach-extract and the two combine card respectively and accompany his influence (n of the shore to tumour inhibiting rate
=8,)
| Group | Dosage (μ g/ml) | Knurl weight (g) | Tumour inhibiting rate (%) |
| Control group | - | 4.42±0.13△ | - |
| Capecitabine group | 300mg/kg | 1.89±0.09* | 57.24 |
| American-cockroach-extract group | 2500mg/kg | 2.78±0.10*△ | 37.10 |
| American cockroach medicinal powder group | 800mg/kg | 2.65±0.13*△ | 40.05 |
| American-cockroach-extract+capecitabine group | 2500mg/kg+300mg/kg | 1.39±0.11*△ | 68.55 |
| American cockroach medicinal powder+capecitabine group | 800mg/kg+300mg/kg | 1.23±0.10*△ | 72.17 |
Note：Compared with control group, * P ＜ 0.05；Compared with capecitabine group, △ P ＜ 0.05.
To sum up, the medicine of the present invention containing capecitabine and American-cockroach-extract, radiated for cancer cell
Property sensitization, tumour inhibiting rate it is stronger than the effect that capecitabine and American cockroach are used alone, illustrate American cockroach and Ka Peita
There is obvious synergistic function after the combination of shore.Its drug combination ratio is：The weight of American-cockroach-extract and capecitabine
Amount proportioning is (1000~2500)：(200~300)；The weight proportion of American cockroach medicinal powder and capecitabine is (500~800)：
(200~300) have good effect.Preferably, American-cockroach-extract 2500mg, capecitabine 300mg, if conversion adult
With dosage (assuming that the body weight of people is 60kg), every daily dosage of optimum proportioning of the present invention should be 18.7g；Another optimal proportion
For American cockroach medicinal powder 800mg, capecitabine 60mg, if converting adult's dosage, every daily dosage of optimum proportioning of the present invention
Should be 7.3g.
Claims (10)
1. a kind of medicine containing American cockroach and capecitabine, it is characterised in that the active component of described medicine includes U.S.
The big Lian in continent and capecitabine；Wherein, described American cockroach is American-cockroach-extract or American cockroach medicinal powder.
2. medicine according to claim 1, it is characterised in that the active component of described medicine by weight, including：
1000~2500 parts of American-cockroach-extract, 200~300 parts of capecitabine；Preferably, 2500 parts of American-cockroach-extract, card
Train his 300 parts of shore.
3. medicine according to claim 2, it is characterised in that the preparation method of described American-cockroach-extract is：It is beautiful
The big Lian in continent, which crushes to be placed in ethanol, to be soaked, and refluxing extraction 2~3 times, is concentrated into no alcohol taste, is obtained extract solution, adds into extract solution
Enter water, after being well mixed, stand, cool down, filtering, be concentrated under reduced pressure, be drying to obtain.
4. medicine according to claims 1 to 2, it is characterised in that the American-cockroach-extract is Kangfuxin Liquid.
5. medicine according to claim 1, it is characterised in that the active component of described medicine by weight, including：
500~800 parts of American cockroach medicinal powder, 200~300 parts of capecitabine；Preferably, 800 parts of American cockroach medicinal powder, capecitabine
300 parts.
6. medicine according to claim 5, it is characterised in that the preparation method of described American cockroach medicinal powder is：
A. adult bombay canary is placed in vacuum desiccator, it is 2~5% to be dried at 20~55 DEG C to water content, obtains drying
Adult bombay canary；
B. the adult bombay canary of the drying obtained in step a is placed in the ultralow temperature powder that temperature setting is -200 DEG C~-50 DEG C
60~300 mesh are crushed in broken machine, produce American cockroach medicinal powder.
7. a kind of compound formulation to cancer with Apoptosis, it is characterised in that it is by American cockroach and Ka Peita
Shore is as active component, the preparation being prepared plus pharmaceutically acceptable auxiliary material or auxiliary element, wherein, described America
Big Lian is American-cockroach-extract or American cockroach medicinal powder.
8. compound formulation according to claim 7, it is characterised in that described American-cockroach-extract and capecitabine
Weight proportion is (1000~2500)：(200~300)；Preferably, the weight proportion of American-cockroach-extract and capecitabine is
2500：300.
9. compound formulation according to claim 7, it is characterised in that described American cockroach medicinal powder and the weight of capecitabine
Amount proportioning is (500~800)：(200~300)；Preferably, the weight proportion of American cockroach medicinal powder and capecitabine is 800：
300。
10. compound formulation according to claim 7, it is characterised in that：Described cancer includes the cancer of the esophagus, nasopharyngeal carcinoma, stomach
Cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174010.2A CN107714732A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and capecitabine and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611174010.2A CN107714732A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and capecitabine and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107714732A true CN107714732A (en) | 2018-02-23 |
Family
ID=61201191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611174010.2A Pending CN107714732A (en) | 2016-12-16 | 2016-12-16 | A kind of medicine containing American cockroach and capecitabine and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107714732A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019893A (en) * | 2007-03-20 | 2007-08-22 | 大理学院 | Process of enriching effective antitumor part of periplaneta americana with polyamide |
| CN101057872A (en) * | 2007-03-20 | 2007-10-24 | 大理学院 | Anti tumor active part of American cockroach prepared with reverse phase material and medical application |
| CN101214262A (en) * | 2008-01-09 | 2008-07-09 | 大理学院 | American cockroaches effective fraction for anti-tumor prepared by macroporous adsorption resin and use |
| CN104383519A (en) * | 2014-10-22 | 2015-03-04 | 王喜功 | Chinese and western medicine composition curing stomach cancer and preparation method for Chinese and western medicine composition |
| CN104546922A (en) * | 2014-12-29 | 2015-04-29 | 王帅 | Anticancer drug with function of enhancing immunity |
| CN105148229A (en) * | 2015-09-10 | 2015-12-16 | 崔海滨 | Formula of effect-enhancing and toxicity-reducing traditional Chinese medicine for combination therapy of tumor chemotherapy |
| CN105878290A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating colon cancer |
| CN105943558A (en) * | 2016-06-21 | 2016-09-21 | 四川好医生攀西药业有限责任公司 | Application of periplaneta americana in preparation of drug for preventing and treating radiation-induced damage |
-
2016
- 2016-12-16 CN CN201611174010.2A patent/CN107714732A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019893A (en) * | 2007-03-20 | 2007-08-22 | 大理学院 | Process of enriching effective antitumor part of periplaneta americana with polyamide |
| CN101057872A (en) * | 2007-03-20 | 2007-10-24 | 大理学院 | Anti tumor active part of American cockroach prepared with reverse phase material and medical application |
| CN101214262A (en) * | 2008-01-09 | 2008-07-09 | 大理学院 | American cockroaches effective fraction for anti-tumor prepared by macroporous adsorption resin and use |
| CN104383519A (en) * | 2014-10-22 | 2015-03-04 | 王喜功 | Chinese and western medicine composition curing stomach cancer and preparation method for Chinese and western medicine composition |
| CN104546922A (en) * | 2014-12-29 | 2015-04-29 | 王帅 | Anticancer drug with function of enhancing immunity |
| CN105878290A (en) * | 2015-07-06 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | Periplaneta americana preparation and applications thereof in preparing medicines for treating colon cancer |
| CN105148229A (en) * | 2015-09-10 | 2015-12-16 | 崔海滨 | Formula of effect-enhancing and toxicity-reducing traditional Chinese medicine for combination therapy of tumor chemotherapy |
| CN105943558A (en) * | 2016-06-21 | 2016-09-21 | 四川好医生攀西药业有限责任公司 | Application of periplaneta americana in preparation of drug for preventing and treating radiation-induced damage |
Non-Patent Citations (6)
| Title |
|---|
| 刘冉 等: "中西医结合治疗晚期胃癌38例疗效观察", 《国医论坛》 * |
| 司新珍: "康复新液合并放疗治疗中晚期食管癌临床观察", 《基层医学论坛》 * |
| 张波: "卡培他滨联合中药治疗晚期消化道肿瘤43例疗效探讨", 《临床医学》 * |
| 曹隽: "康复新液联合化疗治疗急性白血病的疗效观察", 《中国医药指南》 * |
| 田振国: "《中医临床诊疗指南释义 肛肠疾病分册》", 31 October 2015 * |
| 陈春永 等: "卡培他滨联合草酸铂加健脾散结中药治疗晚期复发食管癌的临床观察", 《世界中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108159038A (en) | A kind of pharmaceutical composition and its purposes in the drug for preparing treatment multi-drug resistance of the tumor | |
| WO2019228524A1 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
| CN103520151B (en) | γ-and the medical usage of Delta-Tocopherol and its derivative as radioprotectant | |
| CN111265536A (en) | Antitumor composition containing rare ginsenoside Rk2, CK and PPT | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| CN104351612A (en) | Sea cucumber, lucid ganoderma, glucan and selenium preparation and preparation method thereof | |
| CN100579557C (en) | Cough-stopping granule with honeysuckle flower and bulbus fritilariae | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| CN107714732A (en) | A kind of medicine containing American cockroach and capecitabine and its application | |
| CN100544736C (en) | A kind of pharmaceutical composition of enhancing immunity and preparation method | |
| CN102058854B (en) | Chinese medicine for treating malignant lymphoma | |
| CN101422534B (en) | Radio therapy sensitization composite preparation | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| CN105902561A (en) | Application of Gracilariopsis lemaneiformis polysaccharide as antitumor chemotherapy drug synergist and antitumor drug | |
| CN100438881C (en) | Application of crocodile blood in process for preparing anticancer antivirus and immunity improving medicine and health caring food | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| CN107693546A (en) | A kind of medicine containing American cockroach and Sorafenib and its application | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN107019771A (en) | A kind of antineoplastic Chinese medicine composition | |
| WO2022222388A1 (en) | Use of l-sorbose in preparation of drug for treating tumors | |
| CN109316540A (en) | A kind of strengthening the spleen and stomach acupoint plaster and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180223 |